



19th Executive Board
 Special Session on Proposals
 5 May 2014
 WHO, Geneva

Resolution n°3

HIV/HCV Drug Affordability Project

Taking into account the outcome of the PRC review of 3-4 April 2014 and noting the issues raised for further clarification, the Executive Board of UNITAID, subject to the availability of funds, authorizes the Executive Director to commit up to **USD 5 230 000** for phase 1 of the project *HIV/HCV Drug Affordability Project*.

Description: To work with and through partners in Brazil, China, Ecuador, Egypt, Georgia, Indonesia, Malaysia, Morocco, South Africa, Thailand and Ukraine to advance access to new treatments for hepatitis C and HIV co-infected patients

Lead organization(s): Coalition Internationale Sida

Consortium Members: n/a


Phase 1 duration: 2 years

Conditions for UNITAID funding support:

Funding is conditional upon:

- The development of a Project Plan to the satisfaction of the Secretariat, having regard to the issues raised by the PRC during its review.
- Review of the budget to ensure that all proposed costs are appropriate, reasonable and represent value for money (including with respect to any third-party recipients), to the satisfaction of the Secretariat.
- Development of annual project milestones, to be approved by the Secretariat.
- Signature of a legal agreement for phase 1 between Coalition Plus and UNITAID reflecting performance based funding linked to the milestones.
- Satisfactory performance, based on the agreed milestones and to be assessed by the Secretariat and confirmed by UNITAID's Executive Board annually.
- An independent operational review to be commissioned by UNITAID within one year after project launch.

Any subsequent multi-year funding for this project is dependent on the submission to UNITAID by Coalition Plus of an updated project proposal within one year after project launch, for review by the PRC and a further decision by UNITAID's Executive Board.


 Philippe Douste-Blazy
 Chair of the UNITAID Executive Board